Home » Stocks » PRTG

Portage Biotech, Inc. (PRTG)

Stock Price: $27.99 USD -0.16 (-0.57%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
After-hours: $27.94 -0.05 (-0.18%) Apr 21, 4:00 PM
Market Cap 348.43M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.08M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 21
Last Price $27.99
Previous Close $28.15
Change ($) -0.16
Change (%) -0.57%
Day's Open 28.50
Day's Range 27.03 - 28.86
Day's Volume 6,076
52-Week Range 26.50 - 37.50


Hide News

Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG"Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc.,...

5 days ago - Newsfile Corp

- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to impro...

1 week ago - Newsfile Corp

- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months...

3 weeks ago - Newsfile Corp

About PRTG

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, ... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements